SCHEMBL6978355

SCHEMBL6978355

O=C(O)C1OC1C(=O)NCCC(=O)N1CCN(c2ccccc2Cl)CC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.55
HTR7 P34969 1/20 0.51
TSHR P16473 1/20 0.47
GRM5 P41594 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 2/20 0.46
ADAMTS5 Q9UNA0 1/20 0.45
PARP1 P09874 1/20 0.45
AKR1C3 P42330 1/20 0.44
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
DRD3 P35462 1/20 0.44
KDM4E B2RXH2 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6978349 1.00 GFER (0.55) GFERHTR7TSHRGRM5MEN1
SCHEMBL6978386 0.89 KMT2A (0.49) GFERHTR7TSHRGRM5MEN1
SCHEMBL6978390 0.89 KMT2A (0.49) GFERHTR7TSHRGRM5MEN1
SCHEMBL27484010 0.86 GFER (0.50) GFERHTR7TSHRGRM5MEN1
SCHEMBL6981156 0.84 DRD3 (0.44) GFERHTR7ALDH1A1MAPTAKR1C3
SCHEMBL6978571 0.79 KMT2A (0.44) HTR7TSHRGRM5MEN1KMT2A
SCHEMBL6981803 0.77 ADAM10 (0.40) TSHRGRM5MEN1KMT2ASMN1; SMN2
SCHEMBL6981707 0.77 SMN1; SMN2 (0.43) HTR7TSHRGRM5MEN1KMT2A
SCHEMBL6984624 0.76 GRM5 (0.41) HTR7TSHRGRM5MEN1KMT2A
SCHEMBL6981578 0.76 GRM5 (0.47) HTR7TSHRGRM5MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
CN-1195343-A Piperazine derivatives and use of same SENJU PHARMA CO (JP) 1998-10-07 CN disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
CN-1163145-A Inhibiting agent for vascular formation SENJI SEIYAKU K K (JP) 1997-10-29 CN disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed